ArticleBMC gastroenterology2025
Eosinophilic esophagitis patients report substantial disease burden comparable to more systemic immune-mediated diseases.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEosinophilic esophagitis (EoE) is a chronic Type 2 inflammation. One might assume that the disease-related impact on daily life is significantly smaller, given the relatively localized disease distribution, compared to more systemic immune-mediated diseases. This study aimed to evaluate the disease burden among various immune-mediated diseases, including EoE, inflammatory bowel disease (IBD), systemic sclerosis (SSC) and lupus erythematosus (SLE).
methodsA web-based questionnaire assessed baseline characteristics, general quality of life and disease-related impairment across several subdomains, including work, leisure and social life. The surveys were distributed by the respective Swiss patient organizations.
resultsOverall, 608 patients participated in the survey (EoE: 92; IBD: 407; SSC: 69; and SLE: 40). Although the overall perceived general impairment in everyday life, measured on a numeric rating scale (NRS), was higher in Crohn's disease (CD), SSC, and SLE patients compared to EoE (median 3, IQR 2-6), there was no significant difference compared to ulcerative colitis (UC) (median 4, IQR 2-6, p = 0.31) or IBD patients overall (median 5, IQR 3-6; p = 0.05; Fig. 1a). Impairment in EoE was most pronounced and in the subdomain of leisure, consistent with other investigated diseases. Disease-related impairment was higher in women versus men and in patients with a longer diagnostic delay across all diseases.
conclusionsEoE patients' perceived impairment in everyday life, particularly within subdomains such as leisure, is substantial and comparable to that experienced by patients with other immune-mediated disease states, including IBD. Notably, patient-perceived impairment was higher among female EoE patients and those with a longer diagnostic delay.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.